

## Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temozolomide in patients with advanced solid tumors

Jeffrey R. Infante<sup>1,2</sup> · Roger B. Cohen<sup>3</sup> · Kevin B. Kim<sup>4</sup> · Howard A. Burris III<sup>1,2</sup> · Gregory Curt<sup>5</sup> · Ugochi Emeribe<sup>5</sup> · Delyth Clemett<sup>6</sup> · Helen K. Tomkinson<sup>6</sup> · Patricia M. LoRusso<sup>7</sup>

Published online: 5 July 2017

© The Author(s) 2017. This article is an open access publication

### Erratum to: Invest New Drugs (2017) DOI 10.1007/s10637-017-0459-7

The article A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temozolomide in patients with advanced solid tumors, written by Jeffrey R. Infante, Roger B. Cohen, Kevin B. Kim, Howard A. Burris III, Gregory Curt, Ugochi Emeribe, Delyth Clemett, Helen K. Tomkinson, and Patricia M. LoRusso, was originally published electronically on the publisher's internet portal (currently SpringerLink) on April 19, 2017 without open access.

With the author(s)' decision to opt for Open Choice the copyright of the article changed on July 03, 2017 to © The Author(s) 2017 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

The online version of the original article can be found at <http://dx.doi.org/10.1007/s10637-017-0459-7>

✉ Jeffrey R. Infante  
jinfante@tnonc.com

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

<sup>1</sup> Sarah Cannon Research Institute, 93 Harley St, Marylebone, London W1G 6AD, UK

<sup>2</sup> Tennessee Oncology, PLLC, 250 25th Ave North, Nashville, TN 37203, USA

<sup>3</sup> Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA

<sup>4</sup> California Pacific Medical Center (Sutterhealth), 475 Brannan Street, Suite 220, San Francisco, CA 94107, USA

<sup>5</sup> AstraZeneca, 1800 Concord Pike, Wilmington, DE 19850, USA

<sup>6</sup> AstraZeneca, Charter Way, Macclesfield SK10 2NA, UK

<sup>7</sup> Yale Cancer Center, 55 Park Street, Ste First Floor, New Haven, CT 06519, USA